TW202108171A - 穩定的低黏度抗體調配物及其用途 - Google Patents

穩定的低黏度抗體調配物及其用途 Download PDF

Info

Publication number
TW202108171A
TW202108171A TW109113601A TW109113601A TW202108171A TW 202108171 A TW202108171 A TW 202108171A TW 109113601 A TW109113601 A TW 109113601A TW 109113601 A TW109113601 A TW 109113601A TW 202108171 A TW202108171 A TW 202108171A
Authority
TW
Taiwan
Prior art keywords
formulation
hours
antibody
days
months
Prior art date
Application number
TW109113601A
Other languages
English (en)
Chinese (zh)
Inventor
歐圖 薩盧加
曼裘里 岡谷立
凱文 雷伯特
雅廷 高卡恩
Original Assignee
法商賽諾菲公司
美商健臻公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70295163&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW202108171(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 法商賽諾菲公司, 美商健臻公司 filed Critical 法商賽諾菲公司
Publication of TW202108171A publication Critical patent/TW202108171A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
TW109113601A 2019-04-23 2020-04-23 穩定的低黏度抗體調配物及其用途 TW202108171A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962837518P 2019-04-23 2019-04-23
US62/837,518 2019-04-23
EP20305145 2020-02-17
EP20305145.3 2020-02-17

Publications (1)

Publication Number Publication Date
TW202108171A true TW202108171A (zh) 2021-03-01

Family

ID=70295163

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109113601A TW202108171A (zh) 2019-04-23 2020-04-23 穩定的低黏度抗體調配物及其用途

Country Status (15)

Country Link
US (1) US20220218607A1 (https=)
EP (1) EP3958896A1 (https=)
JP (2) JP7671697B2 (https=)
KR (1) KR20220004104A (https=)
CN (1) CN114286690A (https=)
AU (1) AU2020262231A1 (https=)
BR (1) BR112021021099A2 (https=)
CA (1) CA3137464A1 (https=)
CO (1) CO2021015561A2 (https=)
IL (1) IL287435A (https=)
MA (1) MA55750A (https=)
MX (1) MX2021012968A (https=)
SG (1) SG11202111740PA (https=)
TW (1) TW202108171A (https=)
WO (1) WO2020216847A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
IL293563A (en) * 2019-12-05 2022-08-01 Sanofi Aventis Us Llc Formulations of anti-cd38 antibodies for subcutaneous administration
JP2024546152A (ja) * 2021-12-16 2024-12-17 上海宝済薬業股▲ふん▼有限公司 免疫グロブリン分解酵素による切断に対抗するＦｃ変異体
WO2024023843A1 (en) * 2022-07-26 2024-02-01 Dr. Reddy’S Laboratories Limited A pharmaceutical formulation of a therapeuticantibody and preparations thereof
WO2026006689A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Bcl-xl degrader antibody conjugates and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5460944A (en) * 1991-10-28 1995-10-24 Boehringer Mannheim Gmbh Storable protein solution
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2790018C (en) * 2006-12-21 2015-02-03 Amgen Inc. Formulations
WO2009120684A1 (en) * 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
CN102149825B (zh) 2008-07-08 2015-07-22 Abbvie公司 前列腺素e2双重可变结构域免疫球蛋白及其用途
WO2011028811A2 (en) 2009-09-01 2011-03-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
BR112012008833A2 (pt) 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
AR080428A1 (es) * 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
EP3409289B1 (en) * 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
NZ602685A (en) * 2010-03-01 2014-10-31 Cytodyn Inc Concentrated protein formulations and uses thereof
EP3252072A3 (en) 2010-08-03 2018-03-14 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
JP6345123B2 (ja) * 2012-02-16 2018-06-20 サンタラス， インコーポレイテッド 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物
DK3199552T3 (da) * 2012-11-20 2020-03-30 Sanofi Sa Anti-ceacam5-antistoffer og anvendelser heraf
US20160058863A1 (en) * 2014-09-03 2016-03-03 Board Of Regents, The University Of Texas System Low viscosity concentrated protein dispersions
WO2018119142A1 (en) * 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
TW201837053A (zh) * 2016-12-22 2018-10-16 法商賽諾菲公司 具有消耗活性的人源化cxcr3抗體及其使用方法

Also Published As

Publication number Publication date
CN114286690A (zh) 2022-04-05
CA3137464A1 (en) 2020-10-29
SG11202111740PA (en) 2021-11-29
CO2021015561A2 (es) 2021-12-10
JP2025087851A (ja) 2025-06-10
EP3958896A1 (en) 2022-03-02
KR20220004104A (ko) 2022-01-11
JP7671697B2 (ja) 2025-05-02
BR112021021099A2 (pt) 2021-12-14
US20220218607A1 (en) 2022-07-14
IL287435A (en) 2021-12-01
MA55750A (fr) 2022-03-02
WO2020216847A1 (en) 2020-10-29
AU2020262231A1 (en) 2021-12-16
MX2021012968A (es) 2022-01-18
JP2022530050A (ja) 2022-06-27

Similar Documents

Publication Publication Date Title
TW202108171A (zh) 穩定的低黏度抗體調配物及其用途
JP2024542073A (ja) 抗体薬物結合体のための特異的共役
JP5661553B2 (ja) 改良された抗体分子を含有する製剤
RU2653447C2 (ru) Стабилизированные содержащие антитела жидкие композиции
JP6734774B2 (ja) ペプチドキメラ抗原受容体ｔ細胞スイッチおよびその使用
ES2349779T3 (es) Formulaciones de anticuerpos y de proteínas a concentración elevada.
JP5996631B2 (ja) ＴＮＦＲ：Ｆｃ融合タンパク質の安定した医薬液剤
ES2788515T3 (es) Formulaciones liofilizadas y acuosas de anticuerpos anti-CD40
KR102436694B1 (ko) 약학 조성물
WO2020090979A1 (ja) 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
TWI682788B (zh) 包含ｇｍ－ｃｓｆ中和化合物之液態調配物
CN106163567A (zh) 抗体‑药物缀合物冻干制剂
CN109563161A (zh) 用于提高抗体稳定性的缓冲制剂
ES2806946T3 (es) Composición farmacéutica estable de la proteína de fusión TNFR:Fc etanercept
US20170348427A1 (en) Pharmaceutical formulations and methods of use thereof
AU2011351414A1 (en) Pharmaceutical formulation comprising a biopharmaceutical drug
TW202034961A (zh) 含有標識部－抗人類抗體Ｆａｂ片段複合體之醫藥組成物
JP2022105056A (ja) 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤
CA3193104A1 (en) Pharmaceutical composition comprising antibody-drug conjugate, and use of pharmaceutical composition
US20230414760A1 (en) Pharmaceutical formulation
CN119095584A (zh) 抗gm-csf抗体的液体药物配制品及其用途
US20220280615A1 (en) Immune tolerant elastin-like recombinant peptides and methods of use
BR112022021690B1 (pt) Anticorpos multiespecíficos, biespecíficos ou monoclonais, composição farmacêutica, usos dos mesmos, método de produção dos anticorpos multiespecíficos, biespecíficos ou monoclonais, kit, e moléculas biespecíficas semelhantes a anticorpo de três cadeias
BR122022022755B1 (pt) Anticorpos monoclonais biespecíficos, seus usos e seu método de produção, composição farmacêutica e kit
CN116510006A (zh) 抗trbv9抗体的药物组合物及其用途